Bluebird bio Inc [NASDAQ: BLUE] jumped around 0.1 points on Monday, while shares priced at $1.00 at the close of the session, up 11.14%. Compared to the average trading volume of 8.27M shares, BLUE reached a trading volume of 19912347 in the most recent trading
Bluebird bio Inc [NASDAQ: BLUE] price surged by 0.07 percent to reach at $0.0. The one-year BLUE stock forecast points to a potential upside of 75.6. The average equity rating for BLUE stock is currently 2.77, trading closer to a bullish pattern in the stock
Bluebird bio Inc [NASDAQ: BLUE] closed the trading session at $0.97. The stocks have a year to date performance of -29.67 percent and weekly performance of -1.99 percent. The stock has been moved at -66.06 percent over the last six months. The stock has performed
Bluebird bio Inc [NASDAQ: BLUE] closed the trading session at $1.03. The stocks have a year to date performance of -25.36 percent and weekly performance of -11.21 percent. The stock has been moved at -60.54 percent over the last six months. The stock has performed
Bluebird bio Inc [NASDAQ: BLUE] stock went on an upward path that rose over 8.62% on Tuesday, amounting to a one-week price increase of more than 4.13%. The company report on March 26, 2024 at 7:01 AM that bluebird bio Reports Fourth Quarter and 2023
Bluebird bio Inc [NASDAQ: BLUE] stock went on a downward path that fall over -2.42% on Tuesday, amounting to a one-week price decrease of less than -11.03%. The company report on March 26, 2024 at 7:01 AM that bluebird bio Reports Fourth Quarter and 2023
Bluebird bio Inc [NASDAQ: BLUE] price plunged by -11.76 percent to reach at -$0.16. The company report on March 26, 2024 at 7:01 AM that bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance. – Cash runway through
Bluebird bio Inc [NASDAQ: BLUE] jumped around 0.09 points on Friday, while shares priced at $1.42 at the close of the session, up 6.77%. The company report on March 11, 2024 at 8:00 AM that bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle
Bluebird bio Inc [NASDAQ: BLUE] slipped around -0.11 points on Monday, while shares priced at $1.39 at the close of the session, down -7.33%. The company report on March 11, 2024 at 8:00 AM that bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle
Bluebird bio Inc [NASDAQ: BLUE] price surged by 12.59 percent to reach at $0.18. The company report on January 8, 2024 at 8:00 AM that bluebird bio Provides Update on Commercial Launch Progress, Program Milestones, and 2024 Financial Outlook. Significant momentum behind LYFGENIA launch with
© 2024, Powered by Smart TechOne
